Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis

被引：0
|
作者：
Sizheng Zhao
Laura Chadwick
Eduardo Mysler
Robert J. Moots
机构：
[1] University of Liverpool,Department of Musculoskeletal Biology I, Clinical Sciences Centre, Institute of Ageing and Chronic Disease
[2] Aintree University Hospital,undefined
[3] Organización Medica de Investigación,undefined
来源：
Current Rheumatology Reports | 2018年 / 20卷
关键词：
Adalimumab; Biosimilar; Rheumatoid arthritis; Amgevita; Cyltezo; Imraldi;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501
    Richard Markus
    Helen J. McBride
    Monica Ramchandani
    Vincent Chow
    Jennifer Liu
    Dan Mytych
    Gary Fanjiang
    Advances in Therapy, 2019, 36 : 1833 - 1850
  • [42] The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis
    Braun, J.
    Kay, J.
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (03) : 289 - 302
  • [43] A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis
    Wiens, Astrid
    Correr, Cassyano Januario
    Venson, Rafael
    Otuki, Michel Fleith
    Pontarolo, Roberto
    RHEUMATOLOGY INTERNATIONAL, 2010, 30 (08) : 1063 - 1070
  • [44] A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis
    Astrid Wiens
    Cassyano Januário Correr
    Rafael Venson
    Michel Fleith Otuki
    Roberto Pontarolo
    Rheumatology International, 2010, 30 : 1063 - 1070
  • [45] Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review
    Downey, Colum
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2016, 19 (06) : 536 - 550
  • [46] A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis
    Jani, Rajendrakumar H.
    Gupta, Rajiv
    Bhatia, Girish
    Rathi, Gaurav
    Kumar, Patnala Ashok
    Sharma, Reena
    Kumar, Uma
    Gauri, Liyakat A.
    Jadhav, Praveen
    Bartakke, Girishchandra
    Haridas, Vikram
    Jain, Dinesh
    Mendiratta, Sanjeev K.
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2016, 19 (11) : 1157 - 1168
  • [47] Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn's disease, and chronic plaque psoriasis
    Cohen, Stanley
    Bender, Shaun
    Shaberman, Amy
    Vinisko, Richard
    McCabe, Dottie
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2025, 25 (01) : 133 - 138
  • [48] Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
    Jonathan Kay
    Raymond K. Cross
    Steven R. Feldman
    Younjin Park
    Stephen B. Hanauer
    Advances in Therapy, 2024, 41 : 509 - 533
  • [49] Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
    Kay, Jonathan
    Cross Jr, Raymond K.
    Feldman, Steven R.
    Park, Younjin
    Hanauer, Stephen B.
    ADVANCES IN THERAPY, 2024, 41 (02) : 509 - 533
  • [50] Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
    Gissel, C.
    Goetz, G.
    Repp, H.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2016, 75 (10): : 1006 - 1015
12345